Stockscreener 앱 받기
4.95
5.77%
0.27
시간 외 거래:
4.99
0.04
+0.81%
전일 마감가:
$4.68
열려 있는:
$4.54
하루 거래량:
992.04K
Relative Volume:
2.69
시가총액:
$240.24M
수익:
-
순이익/손실:
$-54.19M
주가수익비율:
-1.9186
EPS:
-2.58
순현금흐름:
$-37.34M
1주 성능:
-1.79%
1개월 성능:
-2.75%
6개월 성능:
-22.41%
1년 성능:
-38.51%
1일 변동 폭
$4.5101
$4.985
1주일 범위
$4.4205
$5.1399
52주 변동 폭
$3.05
$8.45
Abeona Therapeutics Inc Stock (ABEO) Company Profile
명칭
Abeona Therapeutics Inc
전화
646-813-4701
주소
6555 CARNEGIE AVE, 4TH FLOOR, CLEVELAND, NY
ABEO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABEO
Abeona Therapeutics Inc
|
4.95 | 240.24M | 0 | -54.19M | -37.34M | -2.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Abeona Therapeutics Inc Stock (ABEO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-05 | 개시 | Oppenheimer | Outperform |
| 2024-07-03 | 개시 | H.C. Wainwright | Buy |
| 2024-05-30 | 개시 | Stifel | Buy |
| 2020-11-11 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2020-09-18 | 개시 | B. Riley FBR | Buy |
| 2020-02-10 | 개시 | SVB Leerink | Outperform |
| 2019-12-10 | 재개 | Cantor Fitzgerald | Neutral |
| 2019-08-15 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2019-08-12 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2019-07-26 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2019-06-27 | 개시 | Mizuho | Buy |
| 2018-10-12 | 개시 | Mizuho | Buy |
| 2018-06-05 | 개시 | Seaport Global Securities | Buy |
| 2017-11-08 | 개시 | SunTrust | Buy |
| 2017-10-16 | 재확인 | H.C. Wainwright | Buy |
| 2017-10-11 | 재확인 | Cantor Fitzgerald | Overweight |
| 2017-10-10 | 개시 | Citigroup | Buy |
| 2017-10-05 | 재확인 | Maxim Group | Buy |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
| 2017-07-18 | 재확인 | Maxim Group | Buy |
| 2017-06-22 | 재개 | Jefferies | Buy |
| 2017-01-06 | 개시 | Jefferies | Buy |
| 2016-09-29 | 재확인 | Maxim Group | Buy |
모두보기
Abeona Therapeutics Inc 주식(ABEO)의 최신 뉴스
Breakeven On The Horizon For Abeona Therapeutics Inc. (NASDAQ:ABEO) - simplywall.st
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Abeona Therapeutics Expands Team with Strategic Stock Grants for Key New Talent - Stock Titan
Abeona Therapeutics CEO sells shares worth $119,500 - Investing.com India
Abeona Therapeutics CEO sells shares worth $119,500 By Investing.com - Investing.com Australia
Abeona Therapeutics (NASDAQ:ABEO) Upgraded by StockNews.com to Hold Rating - MarketBeat
What is Zacks Small Cap’s Estimate for ABEO Q3 Earnings? - Defense World
What is Zacks Small Cap’s Forecast for ABEO Q1 Earnings? - Defense World
Equities Analysts Set Expectations for ABEO Q1 Earnings - Defense World
Trend Tracker for (ABEO) - news.stocktradersdaily.com
What is HC Wainwright’s Forecast for ABEO Q1 Earnings? - Defense World
Abeona Therapeutics (NASDAQ:ABEO) Given Buy Rating at HC Wainwright - Defense World
Abeona Therapeutics (NASDAQ:ABEO) Upgraded to Hold at StockNews.com - Defense World
Abeona Therapeutics: Positive Outlook Amid FDA Hopes - MSN
Abeona Therapeutics Inc. (NASDAQ:ABEO) Q4 2024 Earnings Call Transcript - Insider Monkey
Abeona planning potential US launch of pz-cel to treat RDEB - Epidermolysis Bullosa News
Abeona Therapeutics Inc (ABEO) Q4 2024 Earnings Call Highlights: Strategic Advancements and ... - Yahoo Finance
Abeona Therapeutics Inc (ABEO) Q4 2024 Earnings Call Highlights: Strategic Advancements and ... By GuruFocus - Investing.com Canada
Abeona Therapeutics Reports 2024 Financial Results - TipRanks
Earnings call transcript: Abeona Therapeutics reports Q4 2024 EPS beat - Investing.com India
Earnings call transcript: Abeona Therapeutics reports Q4 2024 EPS beat By Investing.com - Investing.com UK
Abeona Therapeutics targets $2B revenue potential for pz-cel amid U.S. launch preparations - MSN
Oppenheimer maintains Abeona Therapeutics Outperform rating - Investing.com India
Abeona Therapeutics® Reports Full Year 2024 Financial - GlobeNewswire
Abeona Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
ABEONA THERAPEUTICS INC. SEC 10-K Report - TradingView
Abeona Therapeutics® Reports Full Year 2024 Financial Results, Provides Pz-cel Regulatory - Bluefield Daily Telegraph
Abeona Strengthens to $98M Cash Position as FDA Decision for Pz-cel Approaches - StockTitan
(ABEO) On The My Stocks Page - news.stocktradersdaily.com
Abeona Therapeutics Inc expected to post a loss of 35 cents a shareEarnings Preview - TradingView
Dystrophic Epidermolysis Bullosa Market Forecasted to Surge - openPR.com
Abeona Therapeutics at Leerink’s Global Healthcare Conference: Launch Plans for PZcell - Investing.com Canada
Abeona Therapeutics (ABEO) Projected to Post Earnings on Monday - Defense World
Abeona Therapeutics (NASDAQ:ABEO) Coverage Initiated at Oppenheimer - Defense World
Oppenheimer Initiates Coverage of Abeona Therapeutics (ABEO) with Outperform Recommendation - MSN
This Krystal Biotech Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Oppenheimer Initiates Coverage of Abeona Therapeutics (LSE:0H7R) with Outperform Recommendation - Nasdaq
Trading (ABEO) With Integrated Risk Controls - Stock Traders Daily
Abeona Therapeutics® to Present at the Leerink Partners Global Healthcare Conference - GlobeNewswire
When Abeona Therapeutics Takes the Stage: CEO's Upcoming Leerink Conference Presentation - StockTitan
Abeona Therapeutics announces new employee inducement grants - Yahoo Finance
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Marketscreener.com
How Abeona Therapeutics Is Structuring Compensation to Attract New Talent - StockTitan
Abeona Therapeutics Insider Stock Sales Prove Timely As Market Valuation Descends To US$232m - Simply Wall St
StockNews.com Downgrades Abeona Therapeutics (NASDAQ:ABEO) to Sell - MarketBeat
How the (ABEO) price action is used to our Advantage - Stock Traders Daily
Cell and Gene Therapies in Rare Disorders Market to Skyrocket Across the 7MM During the Forecast Period (2025–2034) | DelveInsight - GlobeNewswire Inc.
Abeona Therapeutics Inc (NASDAQ:ABEO) Short Interest Down 6.8% in January - MarketBeat
HC Wainwright Reaffirms "Buy" Rating for Abeona Therapeutics (NASDAQ:ABEO) - MarketBeat
Abeona Therapeutics’ (ABEO) Buy Rating Reaffirmed at HC Wainwright - Defense World
Epidermolysis Bullosa Market Expected to rise, 2034 | Amryt - openPR
Abeona Therapeutics Inc (ABEO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.23%
1.63%
자본화:
|
볼륨(24시간):